Other Events ·
Immunocore Holdings plc announced the achievement of target patient enrollment in its Phase 3 TEBE-AM clinical trial…
IMCRImmunocore Holdings plc
Immunocore Holdings plc announced the achievement of target patient enrollment in its Phase 3 TEBE-AM clinical trial, which evaluated tebentafusp (KIMMTRAK) as monotherapy and in combination with pembrolizumab for HLA-A*02:01-positive patients with previously treated advanced melanoma. The trial enrolled 540 patients, and the primary endpoint is overall survival. Topline data from this registrational study is expected as early as the end of 2026. Immunocore Holdings plc operates in the biotechnology industry, developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases.